Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs), ‘grandfathering’ and managing lifecycle changes
The guidance covers ‘grandfathering’ and managing the lifecycle changes of medicinal products.
Read the news from Medicines and Healthcare products Regulatory Agency updated on 15 October 2021.
OpenEdition vous propose de citer ce billet de la manière suivante :
lsgilbert (14 mars 2022). Converting Centrally Authorised Products (CAPs) to UK Marketing Authorisations (MAs), ‘grandfathering’ and managing lifecycle changes. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/o5uv





